Citigroup
CGEM icon

Citigroup’s Cullinan Oncology CGEM Stock Holding History

Citigroup’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Sell
124,409
-19,702
-14% -$293K ﹤0.01% 2840
2026
Q1 		$2.05M Sell
144,111
-96,346
-40% -$1.24M ﹤0.01% 2656
2025
Q4 		$2.49M Buy
240,457
+133,282
+124% +$1.2M ﹤0.01% 2515
2025
Q3 		$636K Buy
107,175
+80,684
+305% +$591K ﹤0.01% 3454
2025
Q2 		$199K Sell
26,491
-54,509
-67% -$438K ﹤0.01% 4064
2025
Q1 		$613K Buy
81,000
+327
+0.4% +$3.14K ﹤0.01% 3564
2024
Q4 		$983K Buy
80,673
+42,285
+110% +$608K ﹤0.01% 3383
2024
Q3 		$643K Buy
38,388
+16,281
+74% +$289K ﹤0.01% 3569
2024
Q2 		$386K Sell
22,107
-63,467
-74% -$1.35M ﹤0.01% 3549
2024
Q1 		$1.46M Buy
85,574
+75,004
+710% +$1.16M ﹤0.01% 2717
2023
Q4 		$108K Sell
10,570
-12,964
-55% -$115K ﹤0.01% 4176
2023
Q3 		$213K Buy
23,534
+15,308
+186% +$159K ﹤0.01% 3631
2023
Q2 		$88.5K Sell
8,226
-9,013
-52% -$95.7K ﹤0.01% 4303
2023
Q1 		$176K Buy
17,239
+16,113
+1,431% +$178K ﹤0.01% 3791
2022
Q4 		$11.9K Sell
1,126
-207
-16% -$2.52K ﹤0.01% 4789
2022
Q3 		$17K Sell
1,333
-1,790
-57% -$24.1K ﹤0.01% 4793
2022
Q2 		$40K Sell
3,123
-7,634
-71% -$86.6K ﹤0.01% 4630
2022
Q1 		$113K Sell
10,757
-49,921
-82% -$674K ﹤0.01% 4352
2021
Q4 		$936K Buy
60,678
+57,507
+1,814% +$1.15M ﹤0.01% 3327
2021
Q3 		$72K Buy
3,171
+2,304
+266% +$61.6K ﹤0.01% 4548
2021
Q2 		$22K Sell
867
-1,603
-65% -$49.3K ﹤0.01% 5240
2021
Q1 		$103K Buy
+2,470
New +$100K ﹤0.01% 4340

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citigroup's CGEM Position: Q2 2026 in Review

Citigroup reduced its Cullinan Oncology (CGEM) stake by 14% in Q2 2026, selling an estimated $293K and leaving 124,409 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Citigroup first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.49M in Q4 2025. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Citigroup held 124,409 shares of Cullinan Oncology worth $2.27M as of Q2 2026.
  • Citigroup sold 19,702 Cullinan Oncology shares in Q2 2026, an estimated $293K.
  • Cullinan Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2840 holding.
  • Citigroup first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • Citigroup's Cullinan Oncology position peaked at $2.49M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.